2017
DOI: 10.1007/s10792-017-0536-0
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
4
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(4 citation statements)
references
References 33 publications
0
4
0
Order By: Relevance
“…The course of the disease is slow and progressive. Some patients may be complicated by symptoms such as cataract, glaucoma, and low intraocular pressure and have adverse reactions to the normal function of the eye [5]. At present, the clinical treatment of Coats disease has not yet reached a consensus.…”
Section: Introductionmentioning
confidence: 99%
“…The course of the disease is slow and progressive. Some patients may be complicated by symptoms such as cataract, glaucoma, and low intraocular pressure and have adverse reactions to the normal function of the eye [5]. At present, the clinical treatment of Coats disease has not yet reached a consensus.…”
Section: Introductionmentioning
confidence: 99%
“… 7 Treatments for CNVM include laser photocoagulation, photodynamic treatment, 8 and intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. 9 12 …”
Section: Introductionmentioning
confidence: 99%
“…(Ahnood et al 2017) The current treatment for MFC consists of systemic corticosteroids in the early stage of the disease in order to control the inflammatory component; in the case of active CNV, this treatment can be combined with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF). (Barth et al, 2008;Parodi et al 2013;Niederer et al 2018;Chen et al 2019) Corticosteroid-sparing immunomodulatory therapy (IMT) is widely used for treating noninfectious uveitis to achieve disease control and minimize corticosteroid-related side-effects. (Jabs et al 2000;Galor et al 2008;Niederer et al 2018;Dick et al 2018;Jabs 2018) Recently, the inflammatory component was proposed to trigger the onset and growth of CNV in MFC, suggesting that IMT such as methotrexate and mycophenolate mofetil may be used as a preventive treatment for MFC.…”
Section: Introductionmentioning
confidence: 99%